Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* documented HIV infection~* presence of HIV associated neurocognitive disorders requiring a lumbar puncture for clinical reasons~* treatment or qualifying to be treated with a HIV therapy including darunavir/r (800/100 mg once daily)~* ability to comply with the study requirements~* informed consent~Exclusion Criteria:~* conditions which disrupt the blood-brain barrier and thereby impact the entry of drugs in the brain (meningitis, meningoencephalitis, multiple sclerosis, progressive multifocal leucoencephalopathy)~* co-medications inhibiting/inducing P-glycoprotein and BCRP~* co-medications inhibiting/inducing cytochrome P450 isoenzyme 3A4 (CYP3A4)~* non adherence to Treatment~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darunavir/ritonavir vs cobicistat (Type: EXPERIMENTAL): All HIV infected patients will be treated with a darunavir/ritonavir (800/100 mg) once daily containing regimen. Darunavir/ritonavir concentrations will be measured simultaneously in CSF and plasma after 1 month of treatment. The treatment will be switched to darunavir/cobicistat (800/150 mg) once daily and darunavir/cobicistat levels will be measured in CSF and plasma after 1 month of treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).